{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%281.0ml%29",
    "query": {
      "intervention": "Placebo (1.0ml)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T15:11:54.355Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02582073",
      "title": "Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Placebo (0.5ml)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (1.0ml)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL (0.5ml) 5100SU",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL (1.0ml) 10200SU",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL (1.0ml) 18200SU",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA (0.5ml) 5100SU",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergy Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 265,
      "start_date": "2015-11-07",
      "completion_date": "2017-04-28",
      "has_results": false,
      "last_update_posted_date": "2021-01-29",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02582073"
    },
    {
      "nct_id": "NCT02712151",
      "title": "Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Abdominal Wall Block",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical infiltration",
          "type": "PROCEDURE"
        },
        {
          "name": "Sterile saline",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Ultrasound",
          "type": "DEVICE"
        },
        {
          "name": "Ropivacaine 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-03-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-08",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712151"
    },
    {
      "nct_id": "NCT03931993",
      "title": "A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Placebo comparator",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Grass MATA MPL",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergy Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-01-16",
      "completion_date": "2017-04-27",
      "has_results": false,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 4,
      "location_summary": "Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more",
      "locations": [
        {
          "city": "Edison",
          "state": "New Jersey"
        },
        {
          "city": "Ocean City",
          "state": "New Jersey"
        },
        {
          "city": "Springfield",
          "state": "New Jersey"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03931993"
    },
    {
      "nct_id": "NCT02910635",
      "title": "A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Abnormalities, Cardiovascular"
      ],
      "interventions": [
        {
          "name": "Volanesorsen",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2016-09-19",
      "completion_date": "2016-12-20",
      "has_results": false,
      "last_update_posted_date": "2022-01-28",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02910635"
    },
    {
      "nct_id": "NCT04784767",
      "title": "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride, USP, for injection (0.9% NaCl)",
          "type": "DRUG"
        },
        {
          "name": "50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-05",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784767"
    },
    {
      "nct_id": "NCT02718469",
      "title": "Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Virus Disease"
      ],
      "interventions": [
        {
          "name": "Ebola Vaccine - low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ebola Vaccine - mid dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ebola Vaccine - high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Auro Vaccines LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-12-22",
      "completion_date": "2016-09-15",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 1,
      "location_summary": "Melbourne, Florida",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718469"
    },
    {
      "nct_id": "NCT03580369",
      "title": "A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Ligelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1072,
      "start_date": "2018-10-17",
      "completion_date": "2022-06-14",
      "has_results": true,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580369"
    },
    {
      "nct_id": "NCT03580356",
      "title": "A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Ligelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1078,
      "start_date": "2018-10-20",
      "completion_date": "2022-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-09-18T15:11:54.355Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580356"
    }
  ]
}